Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · IEX Real-Time Price · USD
8.17
-1.31 (-13.82%)
At close: Jul 19, 2024, 12:00 AM
8.21
+0.04 (0.49%)
Pre-market: Jul 22, 2024, 9:11 AM EDT
Adverum Biotechnologies Employees
Adverum Biotechnologies had 121 employees as of December 31, 2023. The number of employees decreased by 2 or -1.63% compared to the previous year.
Employees
121
Change (1Y)
-2
Growth (1Y)
-1.63%
Revenue / Employee
n/a
Profits / Employee
-$933,025
Market Cap
169.58M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
OrganiGram Holdings | 984 |
Metagenomi | 236 |
Repare Therapeutics | 179 |
Rigel Pharmaceuticals | 147 |
TriSalus Life Sciences | 112 |
Syros Pharmaceuticals | 68 |
Acumen Pharmaceuticals | 52 |
Atossa Therapeutics | 12 |
ADVM News
- 5 days ago - Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting - GlobeNewsWire
- 2 months ago - Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights - GlobeNewsWire
- 2 months ago - Adverum Biotechnologies to Participate in Upcoming May Investor Conferences - GlobeNewsWire
- 3 months ago - Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting - GlobeNewsWire
- 4 months ago - Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates - GlobeNewsWire
- 5 months ago - Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference - GlobeNewsWire
- 5 months ago - Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 5 months ago - Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD - GlobeNewsWire